TY - JOUR T1 - High seroprevalence but short-lived immune response to SARS-CoV-2 infection in Paris JF - medRxiv DO - 10.1101/2020.10.25.20219030 SP - 2020.10.25.20219030 AU - François Anna AU - Sophie Goyard AU - Ana Ines Lalanne AU - Fabien Nevo AU - Marion Gransagne AU - Philippe Souque AU - Delphine Louis AU - Véronique Gillon AU - Isabelle Turbiez AU - François-Clement Bidard AU - Aline Gobillon AU - Alexia Savignoni AU - Maude Guillot-Delost AU - François Dejardin AU - Evelyne Dufour AU - Stéphane Petres AU - Odile Richard-Le Goff AU - Zaineb Choucha AU - Olivier Helynck AU - Yves L. Janin AU - Nicolas Escriou AU - Pierre Charneau AU - Thierry Rose AU - Olivier Lantz Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/10/27/2020.10.25.20219030.abstract N2 - Background Although the COVID-19 pandemic peaked in March/April 2020 in France, the prevalence of infection is barely known. Herein, we assessed the serological response against the SARS-CoV-2 virus in a large population working in one institution of the Paris conurbation. We set up two high-throughput and sensitive methods to assess SARS CoV-2 Nucleoprotein and Spike protein-specific IgG response along with a pseudo-neutralization assay in sera. We studied 1847 participants who also answered a web-based survey on clinical symptoms.Methods and Results In May-July 2020, 11% (95% CI: 9.7-12.6) of serums were positive for IgG against the SARS-CoV-2 N and S protein and 9.5% (CI:8.2-11.0) were pseudo-neutralizer. The prevalence of immunization was 11.6% (CI:10.2-13.2) considering positivity in at least one assays. In 5% (CI:3.9-7.1) of RT-qPCR positive individuals, no systemic IgGs were detected. Among immune individuals, 21% had been asymptomatic.Anosmia and ageusia occurred in 52% of the IgG-positive individuals and in 3% of the negative ones. In contrast, 30% of the anosmia-ageusia cases were seronegative suggesting that the true prevalence of infection may reach 16.6%. In sera obtained 4-8 weeks after the first sampling anti-N and anti-S IgG titers and pseudo-neutralization activity declined by 31%, 17% and 53%, respectively with half-life of 35, 87 and 28 days, respectively.Conclusions The population studied being not particularly exposed to SARS-CoV-2 infection is representative of active workers in the Paris conurbation, suggesting that the current epidemiological models may underestimate the true prevalence of infection. The short lifespan of the serological systemic responses hinders retrospective assessment of the epidemic extent.Competing Interest StatementYJ, SG and TR have patented the proluciferins (hikarazines) synthesis and uses (EP 3395803 / WO 2018197727, 2018) and applied for a patent which includes claims describing the LuLISA. FA and PC have applied for a patent claiming the PNT.Clinical TrialThis study was registered and received ethical approval by the Comite de Protection des Personnes Mediterranee III (2020.04.18 bis 20.04.16.49458, 27/4/2020) registered in the clinical trial database (NCT04369066)Funding StatementThis work was made possible thanks to the financial support obtained through the URGENCE nouveau coronavirus fundraising campaign of Institut Pasteur and the financial support of the Fondation Total. This study was funded in part by a grant from Fondation de France and by Institut Curie Institutional funding. The luciferin synthesis development has been supported by DARRI (ValoExpress 2016-2018). LuLISA development has been supported by IARP Pasteur-Carnot MI (2019-2020).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was registered and received ethical approval by the Comite de Protection des Personnes Mediterranee III (2020.04.18 bis 20.04.16.49458, 27/4/2020) registered in the clinical trial database (NCT04369066). Following informed consent, 18 years of age or older volunteer participant outside of any SARS-CoV-2 acute infectious episode in the last 7 days, working at one of the three Institut Curie locations (Paris, Orsay or Saint Cloud) completed a web-based questionnaire (Ennov Clinical) detailed in Supplementary Appendix 1 and 2.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDetailed data are provided as spupplementary information ER -